13 March 2023 - BEAM Alliance

BEAM Alliance published its reflection paper calling for a fair evaluation of the Transferable Exclusivity Extension (TEE) voucher

BEAM Alliance proposes a hybrid model, in which innovation is rewarded by a Transferable Exclusivity Extension (TEE) voucher while, in…

05 September 2023 - BEAM Alliance

BEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics Segment

The new Task Force is gathering innovative SMEs operating in the AMR field and external experts.

24 October 2023 - BEAM Alliance

BEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical Legislation

We call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…

BEAM News
Member News
Events

Latest news of BEAM Alliance

17 September 2024 - BEAM Alliance

BEAM’s Reflection paper on General Pharmaceutical Legislation Revision: Taking Stock of the EU Parliament Position and Moving Forward

The BEAM Alliance would like to reiterate its call for optimal PULL incentives designed to fit innovators’ needs based on…

24 October 2023 - BEAM Alliance

BEAM Alliance shares its views on the ongoing revision of the General Pharmaceutical Legislation

We call on policymakers to stop postponing decisions and either propose a clear incentive package now or reintroduce the TEE…

05 September 2023 - BEAM Alliance

BEAM Alliance is Launching a new Task Force to address Issues from the AMR Diagnostics Segment

The new Task Force is gathering innovative SMEs operating in the AMR field and external experts.

16 June 2023 - BEAM Alliance

BEAM’s reflection paper on the possible roles of DG HERA

The report represents an important step towards the implementation of a tangible solution to fix the AMR market. Although the…

23 May 2023 - BEAM Alliance

BEAM’s statement on the EU Council Recommendation on AMR

The proposal examines AMR in a rather exhaustive way. It includes provisions on the need to strengthen national action plans,…

13 March 2023 - BEAM Alliance

BEAM Alliance published its reflection paper calling for a fair evaluation of the Transferable Exclusivity Extension (TEE) voucher

BEAM Alliance proposes a hybrid model, in which innovation is rewarded by a Transferable Exclusivity Extension (TEE) voucher while, in…

page 1/7

Latest news of BEAM Members

11 September 2024 - BioVersys AG

BioVersys Announces Strategic Investment From GIBF2 and Launch of BV100 Clinical Program in China

We are very pleased to announce this new strategic partnership with the highly regarded investment firm GIBF, which will serve…

06 September 2024 - Basilea

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

We are very pleased with the continued recognition of Cresemba in meeting the critical medical needs of patients with life-threatening…

03 September 2024 - ANTABIO S.A.S

Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310

“With matching PK and good tolerability, MEM-ANT3310 shows great promise to address serious infections whenever multidrug resistance is a concern…

28 August 2024 - Destiny Pharma plc

Destiny Pharma: FDA grants XF-73 Dermal QIPD for burn wound

XF‐73 Dermal's successful US FDA Qualifying Infectious Disease Product application builds on the previously successful US FDA QIDP grant for…

27 August 2024 - Basilea

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

We are very pleased to have received the European Commission Decision to approve Cresemba for the use in children who…

05 August 2024 - Destiny Pharma plc

Destiny Pharma: XF-73 prevents bacterial invasion of bloodstream

These results from an in vivo burn wound infection model provide clear evidence that XF-73 can significantly reduce the risk,…

page 1/58

Events

25 February 2025

9th AMR Conference

Save the date! The 9th AMR Conference will be organized as a face-to-face event on 25-26 February 2025, in Basel.…

04 November 2024

BIO-Europe ® 2024 – 30th Annual International Partnering Conference

Over the last 30 years, BIO-Europe, has become Europe’s flagship partnering event. Its international reach makes it a one-of-a-kind offering,…

19 September 2024

REVIVE Webinar: An introduction to antibiotic research and development (R&D)

Itroduction to the stages from discovery to the phases of clinical trials and pharmaceutical development - A must-watch for clinicians…

22 August 2024

REVIVE Webinar: Exploring non-traditional antimicrobials: Insights from three cases

Find out the latest in the development of non-traditional antimicrobials from Jennifer Schneider at Centauri Therapeutics, Rida Mourtada at Lytica…

23 July 2024

REVIVE Webinar: The value of surveillance data in defining the medical need for new antimicrobials

In this webinar, the speakers will show the value of susceptibility surveillance data in defining the need for new antibacterials,…

27 June 2024

REVIVE Webinar: Progressing an antibacterial drug discovery project – an SME perspective

Alisa Serio from Paratek Pharma and Victoria Savage from INFEX Therapeutics will focus on the particular challenges, progression criteria and…

23 April 2024

REVIVE Webinar: Efflux inhibitors: A strategy to tackle multidrug resistance

The next REVIVE webinar will feature an overview of bacterial efflux and how molecules designed to inhibit this can be…

18 April 2024

BEAM webinar – Swiss RTA: Why do we need a pull incentive to push antibiotics onto the market?

BEAM is excited to host a series of webinars setup by its Associated Organizations.

09 April 2024

REVIVE Webinar: Progressing a discovery project – Criteria and challenges

with Ken Bradley, Global Head, Infectious Disease Discovery, Roche and Diarmaid Hughes, Professor of Medical Molecular Bacteriology, Uppsala University (Sweden)

page 1/18